Market Performance - The Hong Kong stock market indices experienced significant gains, with the Hang Seng Tech Index rising by 2.24%, reaching a new high for the period [1] - In September, the Hang Seng Tech Index accumulated a nearly 14% increase, while the Hang Seng Index and the National Enterprises Index rose by 7.09% and 6.79%, respectively [1][2] Sector Highlights - Major technology stocks saw collective gains, with Kuaishou leading with a rise of over 7%, followed by Alibaba and NetEase with increases of 2% [2][4] - Semiconductor stocks remained strong, with Huahong Semiconductor surging nearly 11% to set a new high [2][8] - Apple-related stocks also saw gains as Apple reportedly notified its supply chain to increase production capacity [2][9] Gold and Copper Stocks - Gold stocks rallied, with Zijin Mining International soaring over 68%, and other gold-related companies also showing strong performance [6] - Copper stocks followed suit, with China Molybdenum rising by 11.84% and Jiangxi Copper gaining over 8% [7] Biopharmaceutical Sector - The biopharmaceutical sector showed positive movement, with WuXi AppTec increasing by over 8% and other companies like Zai Lab and BeiGene also experiencing gains [12][13] Airline Industry - Airline stocks generally rose, with China Eastern Airlines up by 6.73% and both China Southern Airlines and Air China increasing by over 4% [11] - Citic Securities noted strong demand for air travel during the upcoming holidays, suggesting potential for positive performance in the sector [11] Oil and Gas Sector - Oil stocks collectively declined, with China Petroleum falling by 2.75% and other major oil companies also experiencing losses [14] - Reports indicated that OPEC+ plans to increase oil production in November, contributing to the downward pressure on oil prices [14] Gaming and Telecom Stocks - Casino and gaming stocks mostly fell, with Sands China down by 2.25% and other major gaming companies following suit [15] - Telecom stocks also saw declines, with China Telecom and China Mobile both experiencing slight drops [17] Capital Inflows - Southbound capital saw a net inflow of HKD 15.48 billion, indicating strong investor interest in the Hong Kong market [19] Future Outlook - Everbright Securities highlighted the strong overall profitability of Hong Kong stocks, particularly in sectors like internet, new consumption, and innovative pharmaceuticals, suggesting that despite recent gains, valuations remain low and long-term investment potential is high [19]

Core Insights - The article highlights the top and bottom AH share premium rates as of September 30, with Northeast Electric (00042) leading at 831.03% and Ningde Times (03750) at -15.74% [1][2] Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 831.03% with a deviation value of 23.88% [2] - Andeli Juice (02218) follows with a premium rate of 225.72% and a deviation value of -4.44% [2] - Zhejiang Shibao (01057) ranks third with a premium rate of 224.28% and a deviation value of 19.52% [2] Group 2: Bottom AH Share Premium Rates - Ningde Times (03750) has the lowest premium rate at -15.74% with a deviation value of -2.42% [2] - Heng Rui Medicine (01276) shows a premium rate of -3.49% and a deviation value of -2.73% [2] - China Merchants Bank (03968) has a premium rate of 3.79% with a deviation value of -2.91% [2] Group 3: Top Deviation Values - Changfei Optical Fiber (06869) leads with a deviation value of 46.77% and a premium rate of 161.18% [2] - Jihong Co., Ltd. (02603) has a deviation value of 28.09% with a premium rate of 47.76% [2] - Dazhong Public Utilities (01635) ranks third with a deviation value of 24.46% and a premium rate of 128.80% [2] Group 4: Bottom Deviation Values - Longyuan Power (00916) has the lowest deviation value at -26.30% with a premium rate of 152.23% [4] - Qin Port Co., Ltd. (03369) follows with a deviation value of -25.11% and a premium rate of 44.48% [4] - Hongye Futures (03678) shows a deviation value of -20.92% with a premium rate of 215.48% [4]

Group 1 - The Hang Seng Index rose by 0.87%, while the Hang Seng Tech Index increased by 2.24% [1] - Semiconductor stocks experienced significant gains, with Hua Hong Semiconductor rising nearly 11% and SMIC increasing by almost 4% [1] - Spot gold prices reached new highs, leading to a strong performance in gold stocks, with Zijin Mining International surging over 68% and MKS PAMP Group rising more than 4% [1] Group 2 - Ganfeng Lithium and WuXi AppTec both saw increases of over 8%, while Tianqi Lithium rose by more than 5% [1]

Core Viewpoint - The Hong Kong medical sector is experiencing significant gains, with companies like WuXi AppTec rising over 8%, indicating a strong market interest in AI healthcare and CXO services [1] Group 1: Market Performance - The Hong Kong medical sector saw a collective rise, with notable increases in stocks such as WuXi AppTec, Yaoshi Bang, Crystal Tech Holdings, Zai Lab, and MicroPort, reflecting a bullish sentiment in the market [1] - The Hong Kong Stock Connect medical ETF focusing on AI healthcare and CXO (520510) increased by nearly 3%, while the Hang Seng Medical ETF (159892) focusing on innovative drugs rose over 2% [1] Group 2: Industry Trends - Changjiang Securities reports that an increasing number of Chinese pharmaceutical companies are establishing original innovation capabilities and developing mature R&D technology platforms [1] - Chinese innovative pharmaceutical companies are targeting unmet clinical needs and continuously exploring new targets and mechanisms, leading to the emergence of a batch of innovative drugs with international competitiveness, including FIC (First-in-Class) and BIC (Best-in-Class) potential [1]

Group 1 - The CRO sector led the market with a rise of 3.5% on September 30 [1] - Haoyuan Pharmaceutical increased by 6.58% [1] - WuXi AppTec rose by 6.21% [1] - Boteng Co., Ltd. saw an increase of 4.99% [1] - MediSci and Northgrip, as well as Chengda Pharmaceutical, all experienced gains exceeding 4% [1]

Core Viewpoint - The recent announcement by Trump regarding a 100% tariff on all brand/patent drugs starting in October has led to a strong performance in the pharmaceutical sector, particularly among Chinese innovative drug companies, which are not expected to be significantly impacted by this policy [1][1]. Group 1: Stock Performance - Chinese pharmaceutical stocks have shown strong gains, with Heptares Therapeutics (02142) up 8.2% to HKD 15.71, Zai Lab (09688) up 6.83% to HKD 26.6, Innovent Biologics (09969) up 6.61% to HKD 18.87, and WuXi AppTec (603259) (02359) up 5.37% to HKD 115.7 [1][1]. Group 2: Tariff Impact Analysis - Trump's tariff policy applies only to brand/patent drugs and excludes generic drugs, biosimilars, and active pharmaceutical ingredients (APIs) [1][1]. - According to CMB International, the impact on China's innovative drug industry chain is limited, and there is no need for excessive concern [1][1]. - Most Chinese companies have either established production capacity in the U.S. or outsourced production to local Contract Manufacturing Organizations (CMOs), which mitigates the immediate impact of the tariffs [1][1]. Group 3: Export Dynamics - The majority of Chinese innovative drugs exported are in the form of APIs or raw herbal extracts, which are not affected by the new tariff policy, while the proportion of finished drug exports remains low [1][1]. - The investment timeline for multinational corporations (MNCs) to build factories in the U.S. will take time, leading to limited direct impact on CXO orders in the short term [1][1]. Group 4: Future Catalysts - Upcoming catalysts include the ESMO conference scheduled for mid to late October and the results of the medical insurance negotiations along with the first version of the commercial insurance innovative drug catalog expected to be announced in October to November [1][1].

Core Viewpoint - The pharmaceutical sector is experiencing strong performance, with notable stock increases for several companies following Trump's announcement of a 100% tariff on all brand/patent drugs starting in October, which is not applicable to generic drugs, biosimilars, and active pharmaceutical ingredients (APIs) [1] Group 1: Stock Performance - Companies such as HAPO (02142) saw an 8.2% increase, trading at HKD 15.71; Zai Lab (09688) rose by 6.83% to HKD 26.6; Innovent Biologics (09969) increased by 6.61% to HKD 18.87; WuXi AppTec (02359) gained 5.37%, reaching HKD 115.7 [1] Group 2: Tariff Impact Analysis - The new tariff policy is expected to have a limited impact on China's innovative drug industry, as most companies have either established production capacity in the U.S. or outsourced manufacturing to local Contract Manufacturing Organizations (CMOs) [1] - The majority of Chinese innovative drugs exported are in the form of APIs or raw biological extracts, which are not affected by the new tariffs, while the export ratio of finished dosage forms is relatively low [1] Group 3: Future Catalysts - Upcoming catalysts include the ESMO conference scheduled for mid to late October, and the results of medical insurance negotiations along with the first version of the commercial insurance innovative drug catalog expected to be released between October and November [1]

从基金十大重仓股角度 数据显示，国海富兰克林基金旗下1只基金重仓药明康德。国富中证A100指数增强(LOF)（164508）二 季度持有股数1.12万股，占基金净值比例为2.28%，位居第十大重仓股。根据测算，今日浮盈赚取约 6.03万元。 9月30日，药明康德涨5.11%，截至发稿，报110.65元/股，成交36.38亿元，换手率1.35%，总市值 3265.84亿元。 资料显示，无锡药明康德新药开发股份有限公司位于上海浦东新区外高桥保税区富特中路288号,香港铜 锣湾希慎道33号利园1期19楼1910室，成立日期2000年12月1日，上市日期2018年5月8日，公司主营业务 涉及小分子化学药的发现、研发及生产全方位、一体化平台服务,以全产业链平台的形式面向全球制药 企业提供各类新药的研发、生产及配套服务。主营业务收入构成为：化学业务78.37%，测试业务 12.93%，生物学业务6.02%，其他(补充)1.90%，其他业务0.79%。 截至发稿，张志强累计任职时间12年197天，现任基金资产总规模4.51亿元，任职期间最佳基金回报 125.94%， 任职期间最差基金回报5.8%。 风险提示：市场有风险，投 ...

9月30日早盘，药明康德AH股齐涨，均涨逾5%。截至10:02，双双涨超5%。 ...

Summary of WuXi AppTec Co Ltd Investor Day Company Overview - **Company**: WuXi AppTec Co Ltd - **Industry**: Contract Development and Manufacturing Organizations (CDMOs) - **Date of Investor Day**: September 29, 2025 - **Location**: Changzhou, Jiangsu province, China Key Points Industry Insights 1. **R&D Pipeline Contribution**: Small molecules and synthetic new modalities are the mainstay of global R&D, contributing 54% of pipeline candidates in 2024 [2] 2. **Innovation from Small Biopharma**: The share of global R&D spending by small biopharma companies increased from 17% in 2015 to 20% in 2024, projected to reach 26% by 2030 [2] 3. **Venture Capital Funding**: Small molecules received 37% of venture capital funding from 2022 to mid-2025, followed by biologics at 26% and cell/gene therapies at 17% [3] 4. **China's Biopharma Ecosystem**: China's early-stage biopharma companies are approximately half of those in the US, indicating a growing innovation ecosystem [4] 5. **Outsourcing Trends**: The global outsourcing rate to Contract Research Organizations (CROs) rose from 35% in 2015 to 52% in 2024, projected to reach 62% by 2030 [4] Company Performance 6. **Molecular Complexity**: WuXi AppTec's contracts showed increased molecular complexity from 2021 to 2025, with a 22% rise in synthetic steps for long-route molecules and a 63% increase in the proportion of molecules weighing over 600 Daltons [4] 7. **Customer Utilization**: Approximately one-third of active customers in oncology, infectious disease, immunology, metabolic disease, and neuroscience utilize WuXi's discovery services [4] 8. **FDA Approvals**: WuXi produced 20% of novel small molecule drugs approved by the US FDA from 2024 to mid-2025, totaling 8 out of 40 approved drugs [4] Market Position 9. **GLP-1 Contracts**: WuXi currently holds 23 GLP-1 contracts, translating to a 24% market share of pipeline drugs by number [5] 10. **Licensing and M&A Activity**: Of 213 licensing and M&A deals for synthetic drugs globally from 2024 to mid-2025, 62 (or 29%) involved WuXi's customers [5] Financial Metrics 11. **Stock Rating**: The stock is rated as Overweight with a price target of HK$106.00, showing a slight downside from the current price of HK$107.60 [7] 12. **Market Capitalization**: The current market cap is approximately RMB 296.437 billion [7] 13. **Revenue Growth**: Projected revenue growth from RMB 39.241 billion in 2024 to RMB 58.491 billion by 2027 [7] 14. **Earnings Per Share (EPS)**: Expected EPS growth from RMB 3.23 in 2024 to RMB 5.87 in 2027 [7] Risks and Opportunities 15. **Upside Risks**: Potential inflection of Fed rates could lead to increased biotech funding, along with favorable government policies and margin expansion [41] 16. **Downside Risks**: Risks include talent turnover, margin pressure from US business, global competition, and geopolitical risks [41] Conclusion WuXi AppTec is positioned strongly within the CDMO sector, with significant contributions to the global R&D landscape and a robust pipeline of contracts. The company is navigating a competitive environment while capitalizing on growth opportunities in the biopharma space.